Business

AstraZeneca has announced an agreement with Circassia Pharmaceuticals for development and commercialization of the Tudorza and Duaklir dry powder inhalers in the US. AstraZeneca will receive $50 million in Circassia ordinary shares and $100 million on approval of Duaklir in the US or June 30, 2019, whichever comes first. Circassia will have the option to acquire … [Read more...] about Circassia acquires rights to Tudorza and Duaklir DPIs in the US

Vectura met the £9 million calendar year royalty cap on GSK's Ellipta DPI products in 2016, a year earlier than predicted, the company said. The £9 million calendar year royalty cap is included in a legacy Skyepharma/GSK agreement that pays Vectura low single-digit royalties on net sales of Ellipta dry powder inhaler products. The company said that it will record … [Read more...] about Vectura announces that it met royalty cap on Ellipta products a year earlier than expected

According to Hikma Pharmaceuticals, the company has signed a licensing and distribution agreement with Orion Corporation for marketing rights to a budesonide/formoterol Easyhaler DPI for the treatment of asthma and COPD throughout the Middle East and North Africa (MENA). Hikma Vice Chairman and CEO of MENA and Emerging Markets Mazen Darwazah commented, “We are … [Read more...] about Hikma to market Orion’s budesonide/formoterol Easyhaler in the Middle East and North Africa

The United States Patent and Trademark Office (USPTO) has granted Insmed Incorporated US Patent Number 9,566,234, titled, "Systems for treating pulmonary infections," the company said. The patent's claims relate to the use of Insmed's Arikayce liposomal amikacin inhalation solution for the treatment of nontuberculous mycobacteria (NTM) and other pulmonary infections. … [Read more...] about Insmed announces new US patent for Arikayce inhaled amikacin

According to Medical Developments International (MVP), Mundipharma has launched the company's Penthrox methoxyflurane inhaler for or the treatment of moderate to severe pain in trauma patients in France and Belgium, triggering a milestone payment of $2.0 million to MVP. Mundipharma owns the rights to Penthrox in most of Europe outside of the UK and Ireland, where … [Read more...] about Penthrox methoxyflurane inhaler launched in France and Belgium

GSK Consumer Healthcare has announced the US launch of Flonase Sensimist fluticasone furoate nasal spray for the once-daily treatment of seasonal and perennial allergy symptoms. The FDA approved Flonase Sensimist, an over-the-counter version of Veramyst, in August 2016. GSK has been marketing an OTC fluticasone propionate nasal spray as Flonase Allergy Relief in … [Read more...] about GSK launches OTC Flonase Sensimist fluticasone furoate nasal spray in US